Method for prediction of clinical course in disseminated skin melanoma patients |
|||||||||||||||
|
IPC classes for russian patent Method for prediction of clinical course in disseminated skin melanoma patients (RU 2399057):
Method for prediction of effectiveness of neoadjuvant automyelochemotherapy in patients with recurrent breast cancer / 2393484
Prior to begin the therapy, the patient's blood is tested for oestradiol concentration. If the concentration is 18.40 to 29.40 nmol/l, tumour size loss after the neoadjuvant automyelochemotherapy by 67-70% is predicted, that is a partial regress of the tumour, while oestradiol concentration 208.50 to 1541.0 nmol/l enables to predict the tumour size loss by 5-45% that is process stabilisation.
Method for determination severity level of trophological insufficiency in patients with chronic obstructive pulmonary disease / 2390026
Body weight index (BWI) is evaluated; if it is lower than 20 kg/m2, additional analysis is needed to determine the serum leptin concentration. If it is within 16.01±0.64 to 10.15±0.91 ng/ml, the absence of trophological insufficiency is diagnosed, while the values within 5.49±0.46 to 2.26 ng/ml enable to diagnose trophological insufficiency of medium severity, while the values 1.90 to 0.72±0.09 ng/ml indicate severe trophological insufficiency.
Method of forecasting retrocessions of larynx cancer / 2389030
In patients suffering from larynx cancer after surgical oncotomy in the course of dispensary observation levels of androsteron and estradiol in 24-hour collection urine are examined and their ratio to each other are determined. At ratio level more than 3 emergence of disease retrocession or metastasis in the near future is forecasted. At ratio level lower than 3 a long-lasting recurrence-free period is forecasted.
 Diagnostic technique for desynchronosis of hypophysial thyroid system in patients with severe bronchial asthma, previously not taking glucocorticoid therapy / 2382366
Diagnostic technique for desynchronosis of hypophysial thyroid system in the patients with severe bronchial asthma refers to medicine. Substance consists that blood of the patients is radioimmunoassayed for concentration of TSH, T3, T4 hormones. The obtained data are processed to draw a graphic curve of circadian rhythm for each hormone that provides a basis to determine individual acrophase and batiphase time. The acrophase (confidence interval) TSH development biorhythm 9 h 11 min (confidential interval 4 h 57 min to 13 h 26 min), T3 hormone - 15 h 01 min (confidential interval 8 h 05 min to 21 h 57 min) T4 hormone - 16 h 34 min (confidential interval 8 h 55 min to 24 h 13 min), and batiphase of circadian TSH secretion rhythm 21 h to 22 h, T3 - 2 h to 4 h, T4 4 h to 5 h ensure to diagnose apparent desynchronosis of hypophysial thyroid system.
Method for predicting depressive behaviour in aged primate, rates of aging and development of stress-dependent pathological changes / 2377570
Invention refers to medicine and veterinary science and can be used for predicting depressive behaviour of an aged primate, rates of ageing and development of stress-dependent pathological changes. According to the claimed invention, an aged primate is examined for psychoemotional reaction on soft and acute psychoemotional stress effect, molar concentration ratio of cortisol and dehydroepiandrosterone sulphate in peripheral blood plasma and percentage concentration of cortisol in peripheral blood plasma in the evening (20 o'clock 45 minutes - 21 o'clock 15 minutes) to concentration of cortisol in peripheral blood plasma in the morning (8 o'clock 45 minutes - 9 o'clock 15 minutes) to predict depressive behaviour in the aged primate with accelerated rates of ageing and development of stress-dependent pathological changes in depressive reaction on soft and acute psychoemotional stress effect, if molar concentration ratio of cortisol and dehydroepiandrosterone sulphate in peripheral blood plasma is not less than 4.3, and concentration of cortisol in peripheral blood plasma in the evening to concentration of cortisol in peripheral blood plasma in the morning is not less than 66%.
Method of estimating efficiency of neoadjuvant autohemochemotherapy in patients suffering from carcinoma of cervival stump / 2375063
Invention concerns medicine, namely oncology and can be used in estimation of clinical effectiveness factors in treatment of carcinoma of cervical stump. Daily urine is analysed for estradiol content and if decreased after treatment from initial level within 8.44-12.85 nmol/days, positive antineoplastic effect of treatment is stated, and if urine estradiol content is maintained in the treated patients within 8.81-11.38 nmol/days, the absence of antineoplastic effect is stated. The obtained results allow considering dynamics of estradiol content in daily urine of the patients suffering from carcinoma of cervical stump prior to AHCT as an additional laboratory test to estimate efficiency of presented pharmacotherapy. Observed positive clinical effect is confirmed by higher operability and improved life quality of the patients.
Method of determining effeciency of larynx cancer treatment / 2375003
Invention relates to medicine, namely to oncology and can be applied in presence of locally advanced process. In daily urine of patients before treatment tetrahydro-11-desoxycortisol is determined. If its level before treatment does not exceed 2 mcmol/day relapse-free period is forecasted during 2 and more years; initial level of fraction over 2 mcmol/day indicates about disease relapse or metastases during first year after treatment.
Way of forecasting of restoration of menstrual function at patients with nervous anorexia / 2363002
Invention concerns medicine, namely to gynecology, and can be used at treatment of patients with amenorrhea caused by nervous anorexia. Level of leptin is defined in blood serum using enzyme immunoassay method for realisation of the way of forecasting of restoration of menstrual function at patients with a nervous anorexia. Then an index of mass of a body (BMI) and a parity leptin/BMI is counted. In case the parity leptin/BMI makes 0.8 and more - normalisation of menstrual function is prognosticated.
Way of diagnostics of male sterility / 2362167
Invention concerns medicine area, namely to andrology, and concerns diagnostics of male sterility. The way includes studying compaction degree of chromatin of spermatozoids, percentage of defective cells in an ejaculate, level of B in blood serum. On the basis of the received data diagnostic index DI is calculated; its value helps to diagnose sterility, or absence of pathology.
 Method of diagnosing functional hyperprolactinaemia in girls / 2351935
In girls with suspected functional hyperprolactinaemia determined are level of prolactin two hours after falling asleep, concentration of general triiodtrionin, cortisol, and ultra-sound examination of small pelvis organs is carried out in order to determine volume of right ovary. On the basis of obtained data canonical value (K) is calculated by formula, and if K is greater than (-2.28) and lower than 1.27 functional hyperprolactinaemia is determined.
Method for differential diagnostics of mammary diseases in men / 2244308
The present innovation deals with biochemical trials: before the onset of therapy in men one should detect blood content of thyroid hormone - free thyroxine - and at its level being 10.3-12.9 pmol/l one should diagnose mammary cancer, at the level of free throxine being 18.7-31.0 pmol/l - one should predict gynecomastia. The method enables to detect the direction of pathological process and carry out due correction of therapy tactics in men with either gynecomastia or mammary cancer.
Method for predicting the delay of intrauterine fetal development / 2246733
The method deals with studying blood serum of pregnant woman to detect the content of insulin-like growth factor (IGF) and vascular-endothelial growth factor (VEGF) and calculate the coefficient of their ratio: at its value being equal to 28.5 and lower it is possible to diagnose the delay of fetal development.
Method for differential diagnostic of chronic hepatitis and hepatic cirrhosis / 2254577
Thyroglobulin content is determined in blood serum using enzyme immunoassay. When thyroglobulin level is increased by 2 times and more compared in contrast with normal one chronic hepatitis is diagnosed, and when thyroglobulin level is decreased by 1.5-2.5 times in contrast with normal one hepatic cirrhosis is diagnosed.
Method for evaluating combined schizophrenia treatment based on atypical antipsychotic drugs and rations and electroconvulsive shock therapy / 2256181
Method involves determining dehydroepiandrosterone sulfate concentration in blood serum. Its growth above 30% when compared to the initial one being observed, treatment efficiency is determined as negative.
Method for diagnosing obliterated forms of congenital suprarenal gland cortex hyperplasia / 2261447
Method involves applying high effectiveness liquid chromatography for determining cortisol, cortisone 11-deoxycorticosterone, 11-deoxycortisone concentration in blood and free cortisol and free cortisone excretion with urine. Ratios of F/E and FF/FE are calculated, where F is the cortisol level in blood; E is the cortisone level in blood; FF is the free cortisol excretion with urine and FE is the free cortisone excretion with urine. The cortisol level in blood not exceeding norm and at least two of three signs: F/E ratio reduction by 25% and more, FF/FE ratio reduction by 25% and more, free cortisol excretion with urine being equal to 25% and more, obliterated forms of congenital suprarenal gland cortex hyperplasia is diagnosed. Corticosterone level in blood growing by 50% and higher, 21-hydroxylase defect is considered to be the case. 11-deoxycorticosterone and/or 11-deoxycortisone concentration in blood being et or greater than 50%, 11β-hydroxylase defect is considered to be the case.
 Method for diagnosing atrophic gastritis cases / 2262706
Method involves making pepsinogen 1, gastrin and Helicopter pylori infection marker combinations analysis and making input of the obtained results into data processing means comprising operation system, means for receiving, transmitting and processing data. The mentioned data processing means is usable for comparing the measured concentration value of a substance under study to a threshold value associated to the substance under study and producing information as a response to comparison results and additionally to other entered data. A set and software are used for implementing the method.
Method for predicting relapse of mammary cancer / 2263319
In the course of surveying in menopausal women after complex therapy one should state the development of mammary cancer at decreased ratio of estriol concentration to the sum of estrone and estradiol urinary concentrations from 1.68±0.23 in relapse-free patients up to 0.74±0.12 - in patients living without relapses for less than a year, up to 0.65±0.13 in patients living without relapse from 2 up to 6 years and up to 0.50±0.10 in patients with relapse-free period from 6 to 10 years. The innovation provides pre-clinical detection of mammary cancer relapse.
Method for predicting fetoplacental insufficiency in pregnant women with thyroid diseases / 2263919
Except detecting placental lactogen in blood serum one should study the content of alphafetoprotein. At placental lactogen content being below 75% against the norm and content of alphafetoprotein below 70% against the norm it is possible to conclude upon availability of fetoplacental insufficiency.
Method for predicting cholecystitis and cholelithiasis / 2263920
While diagnosing cholecystitis and cholelithiasis due to ultrasound testing one should additionally study blood plasma and bile to detect there the content of prostaglandins PGE2 and PGF2α. At PGE2/PGF2α ratio in blood plasma being equal to 6 and more, and, also, at decreased level of biliary cholecystokinin-pancreosimin by 38% and more, biliary PGE2 by 59% and more and increased level of biliary prostaglandin PGF2α by 5.9 times and more against the norm one should diagnose chlecystitis and cholelithiasis. The innovation enables to detect the above-mentioned diseases at earlier stage.
Method for predicting powerless labor in pregnant nodular goiter surgically treated on goiter occasion during pregnancy under medical supervision / 2273456
Method involves determining thyroid gland node diameter and thyrotropic hormone by applying ultrasonic examination approach. Histological examination is carried out with conclusion concerning morphologic nature being obtained like nodular colloid proliferating goiter or thyroid gland adenoma. Diagnostic index Σ is calculated from formula Σ=0.49*K1+0.07*K2-0.5*K3+1.76*K4-1.53, where K1 is the thyroid gland node diameter; K2 is the TTH concentration; K3 is the nodular colloid proliferating goiter index equal to 1 or 0; K4 is the thyroid gland adenoma index equal to 1 or 0. Diagnostic index Σ being less than zero, conclusions concerning powerless labor threat is to be drawn.
|
FIELD: medicine. SUBSTANCE: method is implemented by blood analysis for total and free triiodothyronine after the termination of integrated treatment to derive the total to free triiodothyronine ratio, and it is within the range 0.26-0.31, steady state is predicted to be kept in the patients; the ratio within the range 0.19-0.22 ensures to predict the disease generalisation. Technical and economic efficiency of the invention consists in the fact that the derived prognosis factor is an informative laboratory covariant of the favourable or unfavourable development of the pathology. EFFECT: clinical application of the method allows for well-timed administration of the appropriate treatment in the patient with high-risk early process generalisation. 1 tbl, 2 ex
The invention relates to medicine, namely to biochemical research in Oncology, and can be used to determine further development of the disease, prognostic factors of treatment after the completion of antitumor activities. Treatment of patients with disseminated melanoma is one of the most difficult problems of modern Oncology and often not possible to achieve a stable positive result. This makes the actual search is available and sufficiently informative laboratory criteria, which, along with clinical prognostic factors, would give an idea of the nature of the further development of the disease in patients after complex antitumor activities. In the development of any pathological process, an important role belongs to the individual characteristics of the organism, caused, in particular, systems for maintaining homeostasis. In relation to malignant growth even against the backdrop of similar morphological and phenotypic properties of the tumor they can contribute in achieving positive treatment outcome, and maintaining the resistance of the organism at the post stage. Thyroid hormone triiodothyronine (T3) is a major hormone regulator of metabolism. Controlling and adapting active is here are the main enzymes of all kinds of metabolic processes to changing endogenous and exogenous conditions, it is involved in the normal physiological state of homeostasis (BTW, Chernysheva Hormones of animals. Introduction to physiological endocrinology. SPb., 1995). In this regard, the content of T3and its dynamics in patients under the influence of the malignant process and/or anti-tumor effects can be considered as a potentially significant factor in the development of the body's response to treatment. This aspect needs to be emphasized that the circulating blood T3is in two forms, free and bound protein-perenosice, mainly with tyroneshum globulin. Linking entering the bloodstream T3protein performs the function on the one hand, protect the body against high concentrations of active compounds, on the other serves as a depot hormone. Free hormone due to an ability to interact with the tissues of the target determines the development of all characteristic for T3physiological effects. Thus, in terms of regulatory impacts is important is not only the total content of T3in the blood, but the ratio of total and free forms of the hormone. Known "Method of predicting tumor recurrence in patients with melanoma (Patent No. 2275637 from 27.04.2006,, bull. No. 12). The method developed for the sick women of reproductive status and the basis of the Academy of Sciences for the determination of the daily excretion of urine sex hormones estrone, estradiol and estriol, and calculate the magnitude of the ratio of estriol excretion to total excretion of estradiol and estrone. Determination of the excretion of estrogen and the ratio in the elimination of separate fractions of hormones authors suggested that after the treatment course and phases of the audit observations. In case of increasing the value of the specified ratios predict relapse in 11-12 months after treatment. The disadvantage of this method is its development, and therefore applicable for patients with melanoma of the skin of women of reproductive age, but do not use the specified factor for prognosis in patients of the opposite sex and women of menopausal status. Known "Method of predicting the course of cancer", selected as a prototype (patent No. 2018835 from 11.12.90, bull. No. 16, from 30.08.94). The authors of the method serves to determine in lymphocytes and neutrophils of blood within 4-45 days the content of histamine and calculate the ratio of the first measure to the last. When the value of this relationship over 0.9 predict complication of the disease in the form of development of recurrence and metastases. The disadvantage of this method is the need for multiple follow-up examinations, whereas the baseline does not provide a perspective on Enki individual character development of the disease. The aim of the invention is the identification of prognostic factors for the development of the disease after a comprehensive cancer treatment of patients with disseminated melanoma. This objective is achieved in that after the completion of the comprehensive treatment of patients determine the blood levels of total and free triiodothyronine, find the ratio of total triiodothyronine free and when its value within the boundaries of 0.26-0.31 in predicting preservation in patients with stable condition during 29-48 months, and when the value in the borders for 0,19 0,22 predict the generalization of disease and death during the 10-22 months. The invention "Method of predicting the course of disease in patients with disseminated melanoma of the skin" is new, because it is unknown the level of medicine in the field of biochemical research in Oncology to determine the further development of the disease, prognostic factors after comprehensive cancer treatment of patients with disseminated melanoma. The novelty of the invention lies in the fact that these biochemical studies indicate a correlation between the ratio of the concentrations of total and free T3in the blood of treated patients and the nature of the disease they have. The dependence allows AEC to consider this test as informative laboratory predictor of favorable or unfavorable development of pathology. The invention "Method of predicting the course of disease in patients with disseminated melanoma of the skin" is industrially applicable as it can be used in health care, hospitals with cancer, oncologic dispensaries, cancer research institutes. "A method of predicting the course of disease in patients with disseminated melanoma of the skin" is as follows: In patients with disseminated melanoma of the skin after the complex treatment including automile and autohemotherapy, radiation therapy, determine the blood levels of total (bound+free) and free triiodothyronine and find the ratio of T3shared/T3free. Later in the process control inspection of treated patients establish or absence of disease, or its generalization, ending in death. When mapping process status in patients on follow-up, with the magnitude of the coefficient of T3shared/T3free after they complete a comprehensive treatment found that in patients in whom it was within the boundaries of 0.26 to 0.3, longer stable condition, patients living within 29-48 months; patients with value ratios are the NTA within the boundaries for 0,19 0,22 there is a generalization of the disease with fatal outcome in terms ranging from 10 to 22 months. The study included 7 patients (5 women, 2 men) with disseminated melanoma. Patients received the combined treatment, including automile, autohemotherapy, radiation therapy and surgery. After treatment in the patients ' blood radioimmunoassay method using a standard test kit company Immunotech (Czech Republic) determined the content of total and free T3expected ratio between total and free forms of the hormone. After discharge from the hospital for sick were carried out follow-up. It has allowed to establish that 4 of the observed patients in the period from 10 to 22 months has been the generalization of malignant process, which ended in death. In 3 patients remains stable condition with no signs of progress of the disease within 29-48 months. Thus, the data presented indicate the links between the features of the post of the disease in patients with disseminated melanoma of the skin and the magnitude of the ratio T3shared/T3free at the stage of completion of treatment. In patients with a shorter post-period steady state it was in borders from 0.19 to 0.22, whereas patients with no signs of the disease factor value of the stake is Alice from 0.26 to 0.31.
The dependence allows us to consider this test as informative laboratory predictor of favorable or unfavorable developments considered pathology. Its clinical use will promote the timely identification of patients with high-risk early generalization process that will allow you to apply adequate therapeutic measures in this category is the patients. Examples of clinical perform a method of predicting the course of disease in patients with disseminated melanoma of the skin": Clinical example 1 The patient-VA, born in 1970, IB. No. 15554/t, came in the YEAR of the city of Shakhty in June 2004, complaining of the presence of tumor in the lumbar region to the left, which appeared from moles 1 year ago. Completed needle biopsy Central Asian. No. 46277-81 amelanotic melanoma. The patient received special treatment at the place of residence. In June 2005 the patient was hospitalized in the Department of radiology, RNII with clinical diagnosis: a generalization of melanoma lumbar region to the left, metastases in the axillary and supraclavicular lymph nodes on the left, RT3N0MB St. II And Ref. Local status: postoperative scar in the lumbar region - without features, in the supraclavicular region to the left is palpated increased to 4 cm lymph node, motionless dense. 24-28.06.2005 was held polychemotherapy according to the scheme: Arenosa - 1000 mg intravenous drip in the 1st and 2nd days on autologous blood; Vincristine 2 mg intravenously at day 1. 28.06.2008, 4-day course of chemotherapy performed trypanophobia the right iliac bone. In separate vials containing 75 ml of bone marrow suspension, after incubation at 37°C for 30 minutes intravenously introduced 100 mg of cisplatin on automatozoni on the background wipe the hydration and forced diuresis. With 29.06.2005, the rate of local remote gamma-therapy (DHT) on the area of the supraclavicular lymph node on the left KIND=3 Gr and SOD=65 sogr taking into account the remaining doses. The clinical effect is regarded as a regression of more than 50%. Treatment the patient endured without hematological and General toxic reactions. For inspection and examination in October 2005, signs of recurrence and metastasis was not detected. 31.10-03.11.2005) underwent a course of chemotherapy No. 2 on autologous blood under the scheme: Arenosa - 1000 mg intravenous drip in the 1st and 2nd days on autologous blood; Vincristine 2 mg intravenous drip in 1 day. Cisplatin 100 mg 4-day intravenous drip on the background of overhydration and forced diuresis. 10.12.2005, performed a blood test to determine the content of total and free TK. The ratio TK shared/TK, equal, free, 0,26. In December 2005, February and March 2006 courses of adjuvant chemotherapy No. 3-5, according to the above scheme. During follow-up until November 2008, the patient's clinical group 3, signs of recurrence and metastasis was not detected. Thus, the patient with the ratio TK General to TK free, equal 0,26, at the end of treatment for 38 months remains stable condition. Clinical example 2 Patient L., born in 1938, IB. No. 2291 G/t, was subjected to combined treatment in the city of the PMC is the logical center (YEAR) Rostov-on-don in 1991 about melanoma skin of the inner surface of the left tibia (surgery+radiation). GA. No. 18157/91 - melanoma, on the second level of invasion according to Clark. In November 2004, the patient asked in RNII with complaints about the presence of tumor on the inner surface of the left thigh with a diameter up to 6 cm was performed needle biopsy of the Central Asian education. No. 29143-144 - detected cells of non-epithelial malignancy of nature, likely melanoma. Clinical diagnosis: melanoma of the skin of the inner surface of the left tibia, the state after the combined treatment in 1991, pTiN0M0, St I, metastases in soft tissue of the left thigh. 08.12.2004, after performing tremenously right Ilium started 1st course automalaxoare. In separate vials containing 75 ml of bone marrow suspension, after incubation at 37°C for 30 minutes intravenously introduced 1000 mg of dacarbazine, methotrexate 25 mg and vincristine 1 mg entered in physiological solution. Methotrexate 25 mg and vincristine 1 mg was administered in 8-day physiological solution. With 16.12.2004, learning gemmoterapii (DHT) on postoperative scar single focal dose (ROD) 3 Gy up to a total focal dose (SOD) 40 sogr. In January 2005, at the control examination education in the soft tissues of the left hip was reduced to 2×3 cm in diameter, "divided" is but a few small knots. With 20.01.2005 was begun on a course of automalaxoare No. 2 according to the same scheme. At the control examination in February 2005 education in the field of postoperative scar is not specified, the peripheral lymph nodes are not enlarged. In February and March 2005, made 2 standard course of adjuvant chemotherapy every three weeks using dacarbazine, methotrexate and vincristine. 31.03.2005, performed a blood test to determine the content of total and free TK. The ratio TK shared/TK, equal, free, 0,19. At the control examination in March 2005, signs of lesion of lymph nodes are not identified but the patient was worried about feeling bad. According to the comprehensive examination (ultrasound, FLO chest) signs of lesion of internal organs are not reliably detected. The patient died in may 2005 Thus, a low ratio TK General to TK free the patient at the post stage was combined with the progression of the disease. Technical and economic efficiency "method of predicting the course of disease in patients with disseminated melanoma of the skin" is that the identified prognostic factors are informative laboratory predictor of favorable or unfavorable development of pathology. Clinical application of the method will allow Sovrem the NGOs to assign the appropriate type of treatment for patients with increased risk of early generalization process. A method for predicting the course of disease in patients with disseminated melanoma of the skin, including biochemical, characterized in that after completion of the comprehensive treatment of patients determine the blood levels of total and free triiodothyronine, find the ratio of total triiodothyronine free and when its value within the boundaries of 0.26-0.31 in predicting preservation in patients with stable state, and when the value in the borders for 0,19 0,22 predict the generalization of the disease.
|
||||||||||||||